Following this activity, participants should be able to (1) Discuss current options for treatment of metastatic castration-sensitive prostate cancer, including triplet therapy with androgen deprivation therapy, chemotherapy, and novel hormone therapy. (2) Describe treatment options and how they are selected for patients with metastatic castration-resistant prostate cancer. (3) Identify common supportive care needs and approaches for patients with metastatic prostate cancer.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95244
- Start Date: 2024-05-02 05:00:00
- End Date: 2024-05-02 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Lantheus - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest